OMEROS CORP business relationships
Companies named in OMEROS CORP’s 10-K filed 2026-03-31, and public companies whose annual reports name OMEROS CORP. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 3.5 / 10
- AI naming
- <1 / 100 Top 67% in its category
- Agent readiness
- 5 / 100
- AI adoption
- 3 / 100
Named in OMEROS CORP’s annual report 4
“During 2025, we sold to Novo Nordisk Health Care AG the exclusive global rights in all indications to develop and commercialize zaltenibart, also known as OMS906, our antibody targeting mannan-binding lectin-associated serine protease-3 ("MASP-3"), the key activator of the alternative pathway of com...” SEC filing
“Concurrent with the closing of the Transaction, Novo Nordisk granted to us exclusive, worldwide, royalty-free, transferrable (solely in connection with a permitted assignment of the APLA), sublicensable (in accordance with the APLA), perpetual and irrevocable (except as set forth in the APLA) licens...” SEC filing
“We expect to continue to incur additional losses until such time as we generate significant revenue from the sale of YARTEMLEA or other commercial products or from our APLA with Novo Nordisk or other partnerships.” SEC filing
“Amendment No. 2 to License Agreement with an effective date of January 25, 2013 between Omeros Corporation and Daiichi Sankyo Co., Ltd.” SEC filing
Companies whose annual reports name OMEROS CORP 1
“In August 2020, the Company entered into a Technology License Agreement (the "Omeros Agreement") with Omeros Corporation ("Omeros"), pursuant to which the Company granted Omeros rights to use the Company's Xtend Fc technology for certain antibody product candidates, including zaltenibart.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.